Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$219.06M+285.60%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jack A. Khattar
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 778
- Beta
- 0.56
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 4.82
Financials
Revenue
$219.06M+285.6%Net Income
$-58.37M-194.4%EBITDA
$-29.59M-244.7%Free Cash Flow
$-5.38M-119.3%EPS (diluted)
$-1.01-185.6%Shares Outstanding (diluted)
58.07M+11.7%Operating Expenses
$163.10MCash & Debt
$372.07MRevenue by Segment (annual)
$1.33BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $718.95M | $-38.55M | $-0.68 |
| 2024 | $661.82M | $73.86M | $1.34 |
| 2023 | $607.52M | $1.32M | $0.02 |
| 2022 | $667.24M | $60.71M | $1.13 |
| 2021 | $579.77M | $53.42M | $1.01 |
| 2020 | $520.40M | $126.95M | $2.41 |
| 2019 | $392.75M | $113.06M | $2.16 |
| 2018 | $408.90M | $110.99M | $2.13 |
| 2017 | $302.24M | $57.28M | $1.13 |
| 2016 | $215.00M | $91.22M | $1.84 |
| 2015 | $144.43M | $14.02M | $0.29 |
| 2014 | $122.05M | $19.87M | $0.47 |
| 2013 | $12.02M | $-92.27M | $-2.90 |
| 2012 | $1.48M | $-46.28M | $-2.65 |
Valuation
SUPNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·41d ago·Neutral
Supernus Pharmaceuticals to Participate in September Investor Conferences ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following September investor conferences:
View source ↗ - Newsglobenewswire.com·44d ago·Neutral
Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD ROCKVILLE, Md., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Professional snowboarder, Chloe Kim, is partnering with Supernus Pharmaceuticals as a compensated ambassador to discuss her journey with attention-deficit/hyperactivity disorder (ADHD) and her treatment plan with Qelbree (viloxazine extended-release capsules), a once-daily, non-stimulant medication for patients 6 years
View source ↗ - Newsbusinesswire.com·46d ago·Neutral
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) to Indivior Pharmaceuticals, Inc. for 1.5401 common shares of Indivior for each share of Supernus.Halper Sadeh encourages Supernus shareholders to click here to learn more about their rights and options or contact…
View source ↗ - Newszacks.com·50d ago·Negative
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock? Investors need to pay close attention to SUPN stock based on the movements in the options market lately.
View source ↗
Earnings
Tue, Nov 3(in 3 weeks)
Consensus estimate $0.61 per share
Typical surprise +63.0% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 3$0.54 vs $0.42beat
- Tue, May 5$0.59 vs $0.28beat
- Tue, Feb 24$0.92 vs $0.28beat
- Tue, Nov 4$1.01 vs $0.82beat
- Tue, Aug 5$0.91 vs $0.47beat
- Tue, May 6$0.42 vs $0.38beat
Estimates and results for SUPN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SUPN officers and directors.
- Bought
- —
- Sold
- $9.0m
0 trades
15 trades
- Bhatt Padmanabh P.sold
- Bhatt Padmanabh P.sold
- Bhatt Padmanabh P.sold
- Bhatt Padmanabh P.sold
- Bhatt Padmanabh P.sold
- Bhatt Padmanabh P.sold
- Khattar Jack A.sold
- Khattar Jack A.sold
85 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Ray Cisneroshouse · CA31 · disclosed Apr 8, 2026 (36d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jan 12, 2026 (32d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Nov 18, 2025 (40d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Apr 7, 2025 (14d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jan 13, 2023 (21d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Dec 15, 2020 (32d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Aug 19, 2020 (33d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jun 16, 2020 (15d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jun 10, 2020 (13d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.